Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1382101 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $24.82Day +6.43%Mkt cap $386M1Y +182.0%Off 52W high −43.4%Vol (1Y) 91.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,964 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.0% of sh out |
| Days to cover4.5d |
| 13F net flow (QoQ)+21.99% |
| Top-10 13F concentration59.8% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$99.6M |
| Earnings (TTM)-$153.6M |
| Net margin−186.5% |
| Sales growth 3Y14.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+114.5% |
| 1Y+182.0% |
| 3Y−44.5% |
| 5Y−85.4% |
| Since incept. (ann.)−20.6% |
Total return through 2026-07-30 · series begins 2018-09-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)91.1% |
| Ann. volatility (3Y)101.5% |
| Sharpe (1Y)1.66 |
| Sharpe (3Y)0.30 |
| Max drawdown (1Y)−44.8% |
| Max drawdown (3Y)−90.7% |
| Beta (3Y vs SPY)2.18 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BVF INC/IL | 1.3M | $31M | 7.56% | new |
| Affinity Asset Advisors, LLC | 1.1M | $27M | 6.46% | +42.9% |
| SAMSARA BIOCAPITAL, LLC | 1.1M | $26M | 6.42% | +419.7% |
| Kynam Capital Management, LP | 872,558 | $22M | 5.27% | +81.9% |
| ORBIMED ADVISORS LLC | 801,144 | $20M | 4.84% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 720,442 | $18M | 4.35% | new |
| PERCEPTIVE ADVISORS LLC | 715,307 | $18M | 4.32% | new |
| RA CAPITAL MANAGEMENT, L.P. | 715,307 | $18M | 4.32% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$2.94 | — | $14.5M | −16.5% |
| 2025-12-31 | 2026-03-23 | — | — | $11.6M | −21.4% |
| 2025-09-30 | 2025-11-06 | — | — | $9.7M | +13.8% |
| 2025-06-30 | 2025-08-07 | — | — | $63.7M | +148.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
